Compare
Prime Medicine, Inc. vs CG Oncology, Inc. vs DBV Technologies S.A. vs CRISPR Therapeutics AG
| Latest fiscal year | Prime Medicine, Inc. PRME | CG Oncology, Inc. CGON | DBV Technologies S.A. DBVT | CRISPR Therapeutics AG CRSP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.63M | $4.04M | $5.64M | $3.51M |
| Revenue growth (YoY) | +55.3% | +254.7% | +35.8% | -90.6% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$201.14M | -$161.00M | -$146.95M | -$581.60M |
| EPS (Diluted) | -$1.35 | -$2.08 | -$1.05 | -$6.47 |
| Operating cash flow | -$162.56M | -$132.35M | -$121.18M | -$345.01M |
| Free cash flow | -$167.09M | -$132.48M | -$121.71M | -$345.93M |
| Cash & equivalents | $63.03M | $32.49M | $194.17M | $347.56M |
| Total assets | $342.73M | $791.59M | $233.72M | $2.27B |
| Total liabilities | $221.87M | $38.99M | $64.95M | $343.43M |
| Shareholders' equity | $120.87M | $752.60M | $168.77M | $1.92B |
| Return on year-end equity | -166.4% | -21.4% | -87.1% | -30.3% |
| Shares outstanding | 180.51M | 80.69M | n/a | 95.89M |
Revenue, most recent five fiscal years
| Fiscal year | Prime Medicine, Inc. | CG Oncology, Inc. | DBV Technologies S.A. | CRISPR Therapeutics AG |
|---|---|---|---|---|
| Latest | $4.63M Ended 2025-12-31 | $4.04M Ended 2025-12-31 | $5.64M Ended 2025-12-31 | $3.51M Ended 2025-12-31 |
| 1 year earlier | $2.98M Ended 2024-12-31 | $1.14M Ended 2024-12-31 | $4.15M Ended 2024-12-31 | $37.31M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $204.0K Ended 2023-12-31 | $15.73M Ended 2023-12-31 | $371.21M Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | n/a | $4.84M Ended 2022-12-31 | $1.20M Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2021-12-31 | n/a | $5.71M Ended 2021-12-31 | $914.96M Ended 2021-12-31 |